Smith & Nephew Crescita futura

Future criteri di controllo 4/6

Smith & Nephew prevede che gli utili e i ricavi cresceranno rispettivamente di 22.5% e 5% all'anno. Si prevede che l'EPS crescerà di 24.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 13.8% in 3 anni.

Informazioni chiave

22.5%

Tasso di crescita degli utili

24.5%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	22.6%
Tasso di crescita dei ricavi	5.0%
Rendimento futuro del capitale proprio	13.8%
Copertura analitica	Good
Ultimo aggiornamento	06 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Investors Still Waiting For A Pull Back In Smith & Nephew plc (LON:SN.)

Oct 31

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Sep 25

Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are

Aug 08

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 11

Smith & Nephew (LON:SN.) Has A Pretty Healthy Balance Sheet

Aug 19

Investors Could Be Concerned With Smith & Nephew's (LON:SN.) Returns On Capital

Jul 17

Smith & Nephew plc (LON:SN.) Shares Could Be 22% Below Their Intrinsic Value Estimate

Jun 11

Smith & Nephew (LON:SN.) Seems To Use Debt Quite Sensibly

May 09

Smith & Nephew (LON:SN.) Will Want To Turn Around Its Return Trends

Apr 09

Calculating The Intrinsic Value Of Smith & Nephew plc (LON:SN.)

Feb 09

We Think Smith & Nephew (LON:SN.) Can Stay On Top Of Its Debt

Nov 21

Returns On Capital Signal Tricky Times Ahead For Smith & Nephew (LON:SN.)

Nov 08

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 99% Above Its Share Price

Oct 26

These 4 Measures Indicate That Smith & Nephew (LON:SN.) Is Using Debt Reasonably Well

Aug 11

There Are Reasons To Feel Uneasy About Smith & Nephew's (LON:SN.) Returns On Capital

Jul 28

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 58% Above Its Share Price

Jun 26

Previsioni di crescita degli utili e dei ricavi

LSE:SN. - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	6,382	713	750	1,238	17
12/31/2025	6,077	597	717	1,110	18
12/31/2024	5,780	432	568	997	17
6/29/2024	5,642	305	301	733	N/A
3/29/2024	5,596	284	241	671	N/A
12/31/2023	5,549	263	181	608	N/A
9/30/2023	5,449	241	102	491	N/A
7/1/2023	5,349	218	22	374	N/A
4/1/2023	5,282	221	66	421	N/A
12/31/2022	5,215	223	110	468	N/A
9/30/2022	5,214	360	213	595	N/A
7/2/2022	5,213	496	315	721	N/A
4/2/2022	5,213	510	392	799	N/A
12/31/2021	5,212	524	469	877	N/A
9/30/2021	5,168	539	632	1,051	N/A
7/3/2021	5,124	553	795	1,225	N/A
4/3/2021	4,842	501	644	1,080	N/A
12/31/2020	4,560	448	492	935	N/A
9/30/2020	4,624	420	420	863	N/A
6/27/2020	4,688	391	347	790	N/A
3/27/2020	4,913	496	554	979	N/A
12/31/2019	5,138	600	760	1,168	N/A
9/30/2019	5,044	649	762	1,127	N/A
6/29/2019	4,949	698	763	1,085	N/A
3/29/2019	4,927	681	674	1,008	N/A
12/31/2018	4,904	663	584	931	N/A
9/30/2018	4,887	690	622	984	N/A
6/30/2018	4,869	717	660	1,036	N/A
3/31/2018	4,817	742	N/A	1,063	N/A
12/31/2017	4,765	767	N/A	1,090	N/A
9/30/2017	4,721	817	N/A	1,011	N/A
7/1/2017	4,677	867	N/A	931	N/A
4/1/2017	4,673	826	N/A	890	N/A
12/31/2016	4,669	784	N/A	849	N/A
9/30/2016	4,680	570	N/A	829	N/A
7/2/2016	4,690	356	N/A	809	N/A
4/2/2016	4,662	383	N/A	920	N/A
12/31/2015	4,634	410	N/A	1,030	N/A
9/30/2015	4,702	513	N/A	1,062	N/A
6/27/2015	4,669	557	N/A	940	N/A
3/27/2015	4,680	499	N/A	837	N/A
12/31/2014	4,617	501	N/A	683	N/A
9/27/2014	4,543	503	N/A	702	N/A
6/28/2014	4,422	523	N/A	753	N/A
3/29/2014	4,349	563	N/A	766	N/A
12/31/2013	4,351	556	N/A	867	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di SN. ( 22.5% all'anno) è superiore al tasso di risparmio ( 2.1% ).

Guadagni vs Mercato: Si prevede che gli utili di SN. ( 22.5% all'anno) cresceranno più rapidamente del mercato UK ( 14.7% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di SN. cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di SN. ( 5% all'anno) crescerà più rapidamente del mercato UK ( 3.5% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di SN. ( 5% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di SN. sarà basso tra 3 anni ( 13.8 %).

Smith & Nephew Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 15%

Smith & Nephew plc Provides Earnings Guidance for the Full Year 2024 and for 2025

Consensus EPS estimates fall by 16%

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 21%

Recent updates

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 15%

Smith & Nephew plc Provides Earnings Guidance for the Full Year 2024 and for 2025

Smith & Nephew plc to Report Fiscal Year 2024 Results on Feb 25, 2025

Investors Still Waiting For A Pull Back In Smith & Nephew plc (LON:SN.)

Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium)

Smith+Nephew Announces Board and Committee Changes

Upcoming dividend of US$0.14 per share

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are

Consensus EPS estimates fall by 16%

First half dividend of US$0.14 announced

First half 2024 earnings: EPS exceeds analyst expectations

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024

Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System

Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.).

Consensus EPS estimates increase by 11%

Smith & Nephew (LON:SN.) Will Be Hoping To Turn Its Returns On Capital Around

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024

Smith & Nephew plc (LON:SN.) Not Flying Under The Radar

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Upcoming dividend of US$0.23 per share

Is Smith & Nephew plc (LON:SN.) Trading At A 30% Discount?

New minor risk - Earnings quality

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Consensus EPS estimates fall by 21%

Final dividend of US$0.23 announced

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Full year 2023 earnings: EPS misses analyst expectations

Capital Allocation Trends At Smith & Nephew (LON:SN.) Aren't Ideal

Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting

Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial

Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd.

Is Smith & Nephew plc (LON:SN.) Trading At A 36% Discount?

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Is Smith & Nephew (LON:SN.) Using Too Much Debt?

Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Smith & Nephew (LON:SN.) Could Be Struggling To Allocate Capital

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Upcoming dividend of US$0.14 per share at 3.0% yield

Smith & Nephew plc Announces Board and Committee Changes

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 65% Above Its Share Price

Smith & Nephew (LON:SN.) Has A Pretty Healthy Balance Sheet

Smith & Nephew plc Increases Revenue Guidance for 2023

First half 2023 earnings released: EPS: US$0.20 (vs US$0.20 in 1H 2022)

Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer

Consensus EPS estimates increase by 10%

Investors Could Be Concerned With Smith & Nephew's (LON:SN.) Returns On Capital

Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System

Smith & Nephew plc (LON:SN.) Shares Could Be 22% Below Their Intrinsic Value Estimate

Now 22% undervalued

Smith & Nephew (LON:SN.) Seems To Use Debt Quite Sensibly

Now 20% undervalued

Insider recently bought UK£117k worth of stock

Smith & Nephew (LON:SN.) Will Want To Turn Around Its Return Trends

Upcoming dividend of US$0.23 per share at 2.6% yield

Chief Human Resources Officer recently sold UK£111k worth of stock

Consensus EPS estimates fall by 12%, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

Smith & Nephew plc, Annual General Meeting, Apr 26, 2023

Calculating The Intrinsic Value Of Smith & Nephew plc (LON:SN.)

We Think Smith & Nephew (LON:SN.) Can Stay On Top Of Its Debt

High number of new directors

CEO & Director exercised options to buy UK£59k worth of stock.